Debra L. Beck and Eugene Braunwald, MD Date Published:  18 Oct 2019 Balancing ischemic risk and bleeding risk after percutaneous coronary intervention (PCI) is an important dilemma for clinicians. Reducing the duration of aspirin after PCI may allow for more prolonged use of potent P1Y12 inhibitors while avoiding aspirin-related bleeding risk. Monotherapy with a P2Y12 inhibitor after aMORE

Debra L. BeckEugene Braunwald, MD Date Published: 11 Sep 2019 Approximately 15% of patients with atrial fibrillation (AF) require percutaneous coronary intervention (PCI) at some point to treat obstructive coronary artery disease (CAD). Current guidelines recommend oral anticoagulation for AF and dual antiplatelet therapy with aspirin and a P2Y12 inhibitor after PCI. However, this triple therapy strategy is associated with highMORE

By Harlan R. Gephart, MD In 2013 the American Academy of Pediatrics (AAP) surveyed its membership of over 70,000 Pediatricians regarding their comfort in diagnosing and treating children and adolescents with mental health concerns.  Sixty-five percent of practicing pediatricians felt they lacked the necessary skills to do so. Forty-five percent felt they lacked the diagnosticMORE

Three new trials published in the past year have pushed the debate on the efficacy and safety of aspirin for primary prevention of cardiovascular disease (CVD) back to the forefront. Abdelaziz et al conducted an updated meta-analysis of recent large trials, including >45,000 individuals from the three new trials, to provide comprehensive and updated information on the efficacy and safety of aspirin for primary prevention of CVD.